CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


IgM and IgG diagnostic kits to SARS-CoV-2Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug986 Elisa-test for IgM and IgG to SARS-CoV-2 Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D000077299 Healthcare-Associated Pneumonia NIH 0.71
D060085 Coinfection NIH 0.58
D053717 Pneumonia, Ventilator-Associated NIH 0.32
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff

During the COVID-19 pandemic several countries have seen a high risk of transmission for health care personnel, with some countries having as many 20-25% of nurses and doctors either infected or showing symptoms of COVID-19. In this prospective cohort study, we will systematically screen all hospital staff in the Capital Region of Denmark for IgM and IgG antibodies against SARS-CoV-2 using a point of care tests and an Elisa kit. Testing will be offered 3 times: In April 2020, Maj 2020 and September 2020. All participants will submit a questionnaire regarding exposures, risk factors and symptoms of COVID-19 in relation to each testing. Follow-up will be through electronic patient records and national registries. We will compare the group of health care personnel with data from a control group of healthy volunteer blood donors from the Danish Blood Donor Study. The aim of the study is to investigate the proportion of hospital staff with SARS-CoV-2 antibodies during the study period compared to a control group representing the Danish population. We will compare the test characteristics of the two methods of testing, a point of care test and Elisa. Further, we will investigate the extent to which prior immunization or infection is protective for future infection with COVID-19.

NCT04346186 COVID Diagnostic Test: IgM and IgG diagnostic kits to SARS-CoV-2 Diagnostic Test: Elisa-test for IgM and IgG to SARS-CoV-2

Primary Outcomes

Description: Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population

Measure: Positive IgM/IgG tests

Time: At inclusion

Description: Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population

Measure: Positive IgM/IgG tests

Time: 1 month

Description: Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population

Measure: Positive IgM/IgG tests

Time: 5 month

Description: Comparison of the resultat from the point of care test and with results from Elisa

Measure: Comparison of the point of care test and Elisa

Time: At inclusion

Description: Comparison of the resultat from the point of care test and with results from Elisa

Measure: Comparison of the point of care test and Elisa

Time: 1 months

Description: Comparison of the resultat from the point of care test and with results from Elisa

Measure: Comparison of the point of care test and Elisa

Time: 5 months

Description: Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19

Measure: Re-infection rate

Time: 180 days

Description: Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19

Measure: Re-infection rate

Time: 360 days

Description: Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up

Measure: IgM/IgG positive participants on follow-up test

Time: 1 month

Description: Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up

Measure: IgM/IgG positive participants on follow-up test

Time: 5 months


No related HPO nodes (Using clinical trials)